

DAFTAR PUSTAKA

- 1 Seiji S, Yuichi A, Hironobu M, Masahio A, Shuzo S, Kaoru S. Prognostic value of pleural effusion in patient with non small lung cancer. *Clinical Cancer Research*. 1997; 3: 47-50.
- 2 Rebecca LS. Cancer statistics 2018. *CA Cancer J Clin*. 2018; 68: 7-30.
- 3 Pusat Data dan Informasi Kementerian Kesehatan RI. Stop kanker. Jakarta Selatan: Kementerian Kesehatan RI; 2015.
- 4 RSUP. Dr. M. Djamil. Rekam medis pasien. Padang: RSUP.Dr.M.Djamil; 2017.
- 5 WHO. WHO report on the global tobacco epidemic. Amerika Serikat: WHO; 2017.
- 6 Siegfried JM. Women and lung cancer: does oestrogen play a role?. *Lancet Oncol*. 2001;2(8):506–513.
- 7 Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. *J Natl Cancer Inst*. 2010;102(18):1413–1421.
- 8 Heather AW, Ellen TC., Scarlett LG, Theresa HMK, Diane F, Christina AC, et al. Lung cancer incidence in never-smokers. *J Clin Oncol*. 2007 Feb 10; 25(5): 472-478.
9. Elisna S, Avissena DP, Nirwan A. A retrospective study: clinical and diagnostic characteristics in advance stage of lung cancer with pleural effusion in Persahabatan Hospital 2004-2007. *J Respir/Indo*. 2010 July; 30:3.
10. Patti AG, Vanessa B, John JC, Catherine K, Mark K, Leslie HS, et al. The IASLC lung cancer staging project: validation of the proposal for revision of T, N, and M description and consequent stage grouping in the forthcoming (seventh) edition of The TNM classification of malignant tumor. *J Thorac Oncol*. 2007; 2: 694-705.
11. Jenny M, editor. A guide for people with cancer, their families and friends. Australia: Cancer council Australia; 2016.
12. Anthony JA, Malcolm VB, Jean GF, Jonathan MS, Simon DS. Epidemiology of lung cancer. *Chest*. 2013 May; 143: 5.

13. Wanging C, Rongshou Z, Hongmei Z, Siwei Z. Epidemiology of lung cancer in China. *Thoracacic Cancer*. 2015; 6: 209-215.
14. James RJ, Robert SF. Terapi mutakhir penyakit saluran pernapasan. In: Lyndon S, editor. *Kanker paru-paru: epidemiologi*. 1st ed. Jakarta: Binarupa Aksara; 1997.p. 435.
15. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman pengendalian risiko kanker paru. Jakarta: Kementerian kesehatan RI; 2018.
16. Betty R, Suharmiati. Gambaran pemakaian tembakau/ rokok pada tumor/ kanker paru di Indonesia. *Buletin Penelitian Sistem Kesehatan*. 2012 Jul 3; 15(3): 298-304.
17. Carole A, Aofe MM, Mischelle SG. Epidemiology of lung cancer. *Semin Intervent Radiol*. 2013; 30: 93-98.
18. Tung ST, Jong YP, Jovanny Z, Sarah MT, Melinda SS, Ted C, et al. Role of nicotine dependence on relationship between variant in The nicotine receptor genes and risk of lung adenocarcinoma. *Plos One*. 2014 Sep 9; 9(9): e107268.
19. Pusat Data dan Informasi Kementerian Kesehatan RI. Perilaku merokok masyarakat Indonesia. Jakarta: Kementerian Kesehatan RI; 2015.
20. Kofi A, David PM, Geoffrey L, John CW, Thomas JL, Li Su, et al. Second hand smoke, age of exposure and lung cancer risk. *Lung Cancer*. 2008 Jul; 61(1): 13-20.
21. Hisayuki S, Adi FG. Somatic mutation of epidermal growth factor receptor signaling pathway in lung cancer. *Int J Cancer*. 2006; 118: 257-262.
22. David AE, Bruce EJ, Lucas CA, Aundrey DG, Sherry LH, Roy SH, et al. Mutation in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in with chemotherapy alone and in combination with erlotinib. *J Clin Oncol*. 2005 Sep 1; 23: 25.
23. Fiamma B, Fabio B, Giuseppina F, Lara F, Antonio C, Diego P, et al. Mutation analysis of the HER2 gene in lung tumors from Caucasian patient: mutation are mainly present in adenocarcinomas with bronchioloalveolar features. *Int J Cancer*. 2006; 119: 2586-2591.
24. Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. *Curr*

- Oncol Rep. 2004 Jul; 6(4): 259-267.
25. Li- Han H, Nei- Min C, Shu- Hui K. Estrogen, estrogen receptor and lung cancer. *Int J Mol Sci.* 2017 Aug 5; 18: 1753.
26. Matthew BS, Xifeng W, Rena :, Ara AV, Margaret RS. Hormone replacement therapy and lung cancer risk: a case- control analysis. *Clin Cancer Res.* 2004 Jan 1; 10: 113-123.
27. Xiaodaong C, Piers M, Jose CL, Joseph GA. Radon- induced lung cancer deaths may be overestimated due to failure to account for confounding by exposure to diesel engine exhaust in BEIR VI miner studies. *Plos One.* 2017 Sep 8; 12(9): e0184298.
28. Rakmetkazhy I, Besimbaev, Olga B. The health effects of radon and uranium on the population of Kazakhstan. *Bers and Bulgak Gen and Envi.* 2015; 37: 18.
29. Kreuzer M, Gerken M, Kreienbrock L, Wellmann J, Wichmann HE. Lung cancer in lifetime nonsmoking result of a case control study in Germany. *British Journal of Cancer.* 2001;84(1): 134-140.
30. Aaron R, James A, Robin L, Alison C. The cellular and molecular carcinogenic effects of radon exposure: a review. *Int J Mol Sci.* 2013; 14: 14024-14063.
31. Seth K, Charles W. Epidemiology of lung cancer in women: risk factor, survival, and screening. *AJR.* 2011 Feb; 196: 287-295.
32. Jonathan MS, Erika AT, Paolo B, Lindsay MH, Susan OM, Michael JT, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. *Clin Cancer Res.* 2009 Sep 15; 15(8): 5626-5645.
33. Charles SDC, Lyn TT, Richard AM. Lung cancer: epidemiology , etiology, and prevention. *Clin Chest Med.* 2013 Des 16; 32(4).
34. Gandomani SH, Tarazoj AA, Ghoncheh SM, Yousefi SM, Delaram M, Salehiniya H. Lung cancer in the world: the incidence, moratlity rate, and risk factors. *WCRI.* 2017; 4(3): e911.

35. Ahmedin J, William DT, Robert ET, Lois T, Susan SD. Lung cancer rates convergence in young men and woman in the United States: analysis by birth cohort and histologic type. *Int J Cancer*. 2003 Feb 21; 105: 101-107.
36. Perhimpunan Dokter Paru Indonesia. Pedoman diagnosis dan penatalaksanaan kanker paru. Jakarta: Perhimpunan Dokter Paru Indonesia; 2003.
37. Sanjeet KM, Thaudem TS, Takhenchangbam DS, Venkatesan A. Clinico-pathology of lung cancer in a regional cancer center in Northeastern India. *Asian Pac J Cancer Prev*. 2013; 14(12): 7277-7281.
38. John ES, John MS, Tim H, Christopher DRF. Manual ilmu penyakit paru In: Djaja SA, editor. *Kanker paru: gejala klinis*. 1st ed. Jakarta: Binarupa Aksara; 1990. p. 600.
39. Zulkifli A. Buku ajar ilmu penyakit dalam. In: Setiati S, Alwi I, Sudoyo AW, Seiyahadi B, Syam FA, Simadibrata M, editors. *Kanker paru: prosedur diagnostik*. 6th ed. Jakarta: FKUI; 2006. p. 1017-1018
40. Maitra A, Kumar V. Buku ajar patologi. In: Kumar V, Cotran RS, Robbins SL, editors. *Paru dan saluran napas atas: tumor paru*. 7th ed. Jakarta: EGC; 2007. p. 560-564.
41. William DT, Elisabeth B, Andrew GN, Yasushi Y, John HMA, Mary BB, et al. The 2015 World Health Organization classification of lung tumors Impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol*. 2015;10: 1243-1260.
42. Kentaro I. Lung cancer: Understanding its molecular pathology and the 2015 WHO clasification. *Frontis in Oncology*. 2017 Aug; 7: 193.
43. Saeed M, Dilip O, Yalda A, Andrea C, Edwin JR. The 7th lung cancer TNM classification and staging system: review of the changes and implications. *World J Radiol*. 2012 Apr 28; 4(4): 128-134.
45. AJCC. lung cancer staging 7th edition. American Joint Committe Cancer. <http://cancerstaging.org/referencestools/quickreferences/documents/lungmedium.pdf> - Diakses Oktober 2018.
46. Picot J, Cooper K, Bryant J. The clinical effectiveness and cost effectiveness of bortezomib and thalidomide in combination regimens with

an alkylating agent and a corticosteroid for the first line treatment of multiple myeloma: a systematic review and economic evaluation. *Health Technol Asses*. 2011 Dec; 15(41): 1-204.

47. Stefan H, Hubert W. Lung cancer: current diagnosis and treatment. *Dtsch Arztebl*. 2009; 106(49): 809-820.
48. Bethesda MD. Small cell lung cancer treatment. United States: National Cancer Institute; 2002.
49. Jonston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. *Cancer*. 1985 Aug 15; 56(4): 905-909.
50. Foteine E, George M, Katerina MA, Nikolas MS. The angiogenic pathway in malignant pleural effusion: pathogenetic and therapeutic implications (review). *Exp and Thera Med*. 2010; 1: 3-7.
51. Sahn SA. Pleural diseases relate to metastatic malignancies. *Eur Respir J*. 1997; 10: 1907-1913.
52. Yao C, Nicholas WM, Hongdal. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patient with non small cell lung cancer (review). *Mol Med Rep*. 2018; 17: 8019-8030.
53. Jung HH, Koun SS, Seung IP, Tae HL, Kui HL, Dong EG. Subtle pleural metastasis without large effusion in lung cancer patients: preoperative detection on ct. *Korean J Radiol*. 2005 June; 6(2): 94-101.
54. Anurag A, Rajeev T, Lalit S, Aakanksha C. Clinico pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P with special reference to lung cancer. *Lung Inda*. 2015 Jul-Aug; 32: 4.
55. Ramakant D, Agarwal KC, Archana G, Chetan BP, Manoj M, Narender SS, et al. Diagnosis and management options in malignant pleural effusions. *Lung Inda*. 2017 Mar-Apr; 34(2): 160-166.
56. Neeraj RD, Hans JL. Diagnosis and management of malignant pleural effusions: state of the art in 2017. *J Thorac Dis*. 2017; 9(S10): S1111-S1122.

- 57 Konstantinos Z, Paul Z, Kaid D, Kosmas T, Nikolaos M, Loanna K, et al. Malignant pleural effusion and algorithm management. *J Thorac Dis.* 2013; 5(S4): S413-S419.
- 58 Wande NI. Buku panduan intrepetasi analisis cairan pleura. In: Wande NI, editor. 1st ed. Denpasar: Bagian patologi klinik fakultas kedokteran Udayana; 2016. p. 5-14.
- 59 Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis. In: Sastroasmoro S, Ismael S, editors. Desain penelitian: case control dan perkiraan besar sampel: studi kasus kontrol tidak berpasangan. 5th ed. Jakarta: Sagung Seto; 2014. p. 113;373.
- 60 RSUP.Dr.M.Djamil. Rekam medis pasien. Padang: RSUP.Dr.M.Djamil; 2010-2014.
61. Dahlan SM. Besar sampel dan cara pengambilan sampel. In: Suslia A, editor. Cara pengambilan sampel: concecutive sampling. 3rd ed. Jakarta: Salemba Medika; 2010. p. 139-140.
- 62 CDC. History of smoking. Amerika Serikat: CDC; 2017.
- 63 Perhimpunan dokter paru Indonesia. Panduan diagnosis dan penatalaksanaan PPOK. Jakarta: Perhimpunan dokter paru Indonesia; 2003.
64. Lynn SB. Buku ajar pemeriksaan fisik dan riwayat kesehatan. In: Lynn SB, editor. Tinjauan anamnesis dan pemeriksaan fisik: riwayat medis. 11th ed. Jakarta: IKAPI; 2012. p. 3.
- 65 Walter JB, Pryce DM. The histology of lung cancer. *Thorax.* 1955; 10:107.
66. Notoatmodjo S. Metode penelitian kesehatan. In: Notoatmodjo S, editor. revisi ed. Jakarta: Rineka Cipta; 2010. p. 180.
- 67 Jeong SR, Hyo JR, Si NL, Azra M, Seul KL, Hae SN, et al. Prognostic impact of minimal pleural effusion in non small cell lung cancer. *J Clin Oncol.* 2014 March 20; 32(9): 960-967.
- 68 Semiha EU, Birsen Y, Eda E, Nedim T. Prognostic factors in stage III non small cell lung cancer patients. *Asian Pac J Cancer Prev.* 2016 October 17; 17(10): 4693-4697.
- 69 Charles SDC, Lynn TT, Richard AM. Lung cancer: epidemiology,

- etiology, and prevention. *Clin Chest Med.* 2011 Dec; 32(4): 1-61.
- 70 Jemi O, Yolanda C. Gender differences in lung cancer: have we really come a long way, baby?. *The JT and Cardiovascular Surgery.* 2004 Sep; 128: 3.
- 71 Steen M, David R, Allan H, David HP, Aage H. Sex differences in lung cyp1a1 expression and dna adduct levels among lung cancer patients. *Cancer research.* 1999 July 15; 59: 3317-3320.
- 72 Elizabeth MST, Widiraharjo. Karakteristik penderita efusi pleura di RSUP. Adam Malik tahun 2011. *E-Jurnal FK USU.* 2013; 1(2).
- 73 Rong B, Li M, Fu T, Gao W, Liu H. Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer. *BMC Pulmonary Medicine.* 2018; 18: 188.
- 74 Yu Z, Li KY, Guo JL, Ning X, Hai YX, Wei H, et al. Prognostic value of VEGF and endostatin with malignant pleural effusions in patient with lung cancer. *Asian Pac J Cancer Prev.* 2014; 15(19): 8435-8440.
- 75 Zhe W, Minghuan L, Feifei T, Li K, Jinming Y. Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma. *Cancer management and research.* 2019; 11: 2269-2280.
- 76 Jerzy K, Grzegorz K, Irena P, Kataryzna SM, Marcin G. Lung cancer in patients under the age of 40 years. *Wspolczesna Onk.* 2012; 16(5): 413-415.
- 77 Marios EF. Pleural effusion in lung cancer: more question than answer. *Respiration.* 2012; 83: 367-376.
- 78 Emine Y, Suzanne M. Tobacco nitrosamines as culprits in disease: mechanisms reviewed. *J Physiol Biochem.* 2016 March; 72(1): 107-120.
- 79 Hyun WL, Sung HP, Mao WW, Hsiang TW, William CH, Herbert L, et al. E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. *PNAS.* 2018 29 June: E1560-E1569.
- 80 Peter GS. Molecular epidemiology of smoking and lung cancer. *Oncogene.* 2002 21: 6870-6876.

- 81 Anthanasios V, Thomais V, Konstantinos F. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanism of oxydative damage, carcinogenesis and sinergystic effect with other respirable particles. *Int J Environ Res Public Health*. 2009; 6: 445-462.
- 82 Azad N, Rojanasakul Y, Vallyathan V. Imflamation and lung cancer: roles of reactive oxygen species . *JT Environ Health*. 2008 Jan; 11(1): 1-15.
- 83 Muhammad F. Tobacco smoking and lung cancer. *SQU Medical Jurnal*. 2013 Aug; 13(3): 345-358.
- 84 Herlina, Siti R, Yulia ID. Hubungan riwayat merokok dengan stadium ca paru. *J Online Mahasiswa*. 2014; 1(1).
- 85 Navneet S, Ashutosh NA, Dheeraj G, Digambar B, Surinder KJ. Quantified smoking status and non small lung cancer stage at presentation: analysis of a north indian cohort and sythematics review literature. *J Thorac Dis*. 2012; 4(5): 474-484.
- 86 Jay HL, Neil EC. Cigarette smoking and lung cancer: modelling total exposure and intensity . *Cancer epidemiol biomarker prev*. 2006; 15(3): 517-523.
- 87 Patricia MG, Carol CW, Brett WC, Reginald EM. The epidemiology of lung cancer. *Trand lung cancer res*. 2018; 7(3): 220-233.
- 88 Wooho B, Jong ML, Jick HH, Chang DY, Hyeon HK, Chin KR, et al. Dyspnea as a prognostic factor in patients with non small lung cancer. *Yonsei Med J*. 2016 Sep; 57(5): 1063-1069.
- 89 Linda S, Lorraine E, Donald T, Geraldine P, Carmark H, Marry LB, et al. Impact of respiratory symtoms and pylmonary function on quality of life of long term survivor of non small lung cancer. *Chest*. 2004 Feb; 125(2): 439-445.
- 90 Mitrouska I, Klimathianaki M. Effects of pleural effusion on respiratory function. *Can Respir J*. 2004; 11(7): 499-503.
- 91 Rajesh T, Susan J, Peter RE, Gary L, Bhajan S. Physiology of breathlessness associated with pleural effusion. *Curr Opin Pulm Med*. 2015; 21: 338-345.
- 92 Peter ME, Rachel V. Delays in the diagnosis of lung cancer. *J Thorac Dis*.

2011 Sep; 3: 183-188.

- 93 Labbe C, Anderson M, Simard, Tremblay, Laberge F, Vaillancourt R, et al. Wait times for diagnosis and treatment of lung cancer: a single centre experience. *Curr Oncol*. 2017 Dec; 24(6): 367-373.
- 94 Amelia WM, Stephen AD, Rhonda P, Carol CL, Pierre PM, Robert SD, et al. Timeliness of care and lung cancer tumor stage progression: how long can we wait?. *Ann Thorac Surg*. 2017 Dec; 104(6): 1791-1797.
- 95 Canadian Strategy for Cancer Control. The canadian strategy for cancer control: a cancer plan for canada. 2001 Jan 18; 2: 1-23
- 96 Adiatma, Fatur NK. Hubungan carcinoma paru dengan efusi pleura. *Jurnal Media Medika Muda*. 2012; 1: 1-13.
- 97 Ximing T, Hiyasuki S, Nekele NB, Jack AR, John DM, Waum KH, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer. *Cancer Res*. 2005 1 Sep; 65(17): 75-68-7572.
- 98 David RG, Peter SH, Martin LS, Primo NL, Frennd RH. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. *Cln Cancer Res*. 2015 May 15; 21(10): 2236-2243.

